SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive FDA feedback, which confirms a clear regulatory path for its lead drug in hidradenitis suppurativa without requiring additional clinical trials. This significant de-risking event has revitalized community discussions, with many investors anticipating substantial revaluation and renewed buyout speculation, especially given past acquisition interest and the drug's potential across a broader range of inflammatory conditions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending due to its subsidiary Airobotics securing a pivotal contract as the prime contractor for Israel's border security drone system. This news, amplified by broader discussions surrounding increased global military budgets and strong institutional accumulation, has fueled community excitement and positioned Ondas as a burgeoning leader in the autonomous defense and counter-drone technology sector.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after reporting robust Q2 earnings that surpassed expectations for both revenue and profitability, largely driven by its rapid expansion into high-performance computing. The community is actively discussing the company's strong pipeline, including advanced negotiations for substantial new data center capacity, which is fueling anticipation of significant long-term growth and potential pressure on short positions.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after releasing interim Real-World Evidence data demonstrating DefenCath's significant efficacy in reducing bloodstream infections and hospitalizations. While the community recognizes this as strong validation for DefenCath's potential as a standard of care and its market exclusivity, discussions also reflect ongoing frustration over the stock's price action and perceived market manipulation, alongside the broader impact of the Melinta acquisition.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

FLYX is experiencing significant trading activity after announcing its role as an authorized Starlink Aviation dealer, integrating high-speed connectivity into its private jet services. The community is actively discussing the low float and potential for a short squeeze, with many anticipating a substantial move while others caution about profit-taking and volatility. This news positions the company at the forefront of in-flight innovation within the private aviation sector, driving widespread interest.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is trending after providing an update and outlook that emphasized strong growth for its AI-powered Nociscan back pain platform and a solid, debt-free financial status. Community discussion centers on the company's exceptionally low public float, fueling expectations for sharp price movements, though some investors remain wary given its history of share structure adjustments. This puts the company at the forefront of conversations around innovative diagnostics in the medtech space.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is heavily discussed as Alphabet recently surpassed its market capitalization, intensifying community concerns over Apple's perceived lagging AI strategy compared to tech peers. Many investors are expressing frustration over the stock's consistent decline amidst broader market strength, prompting debates on its innovation and future product roadmap while others see the dip as a compelling buying opportunity.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is generating buzz following news of its collaboration with NVIDIA to integrate advanced AI computing into future aircraft and its strategic moves to launch air taxi trials in major U.S. cities under a White House eVTOL program. The community is actively debating the significance of these developments for the company's long-term potential in both urban air mobility and defense applications, with many anticipating a significant upside while others remain cautious about the near-term execution and market reaction.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is drawing significant attention as it secures major commercial agreements, including a substantial fuel cell deal with AEP and a large purchase order from Quanta, enhancing its role in powering data centers. The market is actively discussing Bloom Energy's potential as a critical energy infrastructure provider for the expanding AI industry. While many celebrate its growth, others highlight its considerable volatility and debate its current valuation, noting strong institutional interest and diverse trading strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows.&nbsp;</li><li>Tradipitant previously failed in gastroparesis but is now under FDA review with labeling discussions underway.</li><li>Approval could open a motion-sickness market estimated at $670 million in 2025.</li></ul>Vanda Pharmaceuticals (VNDA) is facing a moment of reckoning as it awaits an FDA nod for its motion-sickness treatment candidate. After a so-so performance for much of the year, the&nbsp;<a href="https://stocktwits.com/symbol/VNDA">Vanda stock</a> rally kicked off in the middle of November and has been going strong ever since.&nbsp;Between Nov. 14 and Friday’s trading session, the stock has gained about 62%, wiping out the year's losses.<h2 class="st-heading-2">Binary Event Beckons</h2>More than 13 years after licensing NK-1R from Lilly (LLY) for a $1 million upfront payment—and over a year after the FDA rejected its application in gastroparesis—Vanda is once again knocking on the regulator’s door, this time seeking approval for motion sickness. Vand has since rechristened the drug candidate as tradipitant.&nbsp;Last September, the drug regulator issued a Complete Response Letter (CRL) to the new drug application (NDA) for tradipitant for treating symptoms of gastroparesis. A CRL is a letter stating that the agency will not approve a regulatory application in its current form.Reacting to the decision, Vanda said:<blockquote>“The CRL was conclusory in nature, generally disregarded the evidence provided and instead suggested that Vanda conduct additional studies with a design and duration inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding and natural course of the disorder.”</blockquote>Vanda has looked past the disappointment and is hoping for good news. Providing a regulatory update on tradipitant as a preventive treatment for motion sickness-induced vomiting in late November, Vanda stated that the Prescription Drug User Fee Act (PDUFA) target date of Dec. 30 for completion of the review remained unchanged. It also confirmed that the FDA recently issued comments on the proposed labeling and that labeling discussions have formally commenced. If approved, Vanda will have the distinction of delivering the first new pharmacologic treatment for motion sickness in over four decades.According to Mordor Intelligence, the total addressable opportunity for motion sickness is around $670 million in 2025. This is expected to grow at a 3.1% compounded annual growth rate (CAGR), reaching $781 million by 2030.Tradipitant earlier produced positive results in a study that evaluated it as a treatment option for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults.In other recent developments, Vanda announced in early December that the FDA had lifted the partial clinical hold on the tradipitant protocol, which had limited the doses that could be administered. This decision allows Vanda to extend clinical studies of tradipitant in motion sickness.In mid-December, the company said it had submitted a Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis (GPP). It expects to end the year with $260 million to $290 million in cash.&nbsp;Founded in 2003, Vanda focuses on new technologies, including genetics and genomics, for drug discovery, clinical trials, and commercial positioning. The company sells Hetlioz as a treatment for sleep-wake disorder, Fanapt, an antipsychotic medication, and Ponvory for relapsing multiple sclerosis. Vanda generates net product sales of $158.9 million for the first nine months of 2025, marking 9% year-over-year (YoY) growth.&nbsp;<h2 class="st-heading-2">Upcoming Catalysts</h2>Apart from the imminent FDA decision, the company has a slew of catalysts that can propel the stock higher if they pan out favorably. Key among the catalysts are:-FDA decision date for Feb. 21, 2026, for Bysanti (milsaperidone) NDA for bipolar I disorder and schizophrenia-Re-review of the supplemental NDA for Hetlioz for the treatment of jet lag disorder by Jan. 7, 2026<h2 class="st-heading-2">What Analysts and Retail Traders Feel About Vanda</h2>Initiating coverage of Vanda stock with a ‘Buy’ rating and a $11 price target in early November, B. Riley said Vanda is a commercial-stage turnaround story trading at a "historic discount,” the Fly reported. The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines,” the firm said.<img src="https://news.stocktwits-cdn.com/Vandas_Valuation_PS_png_bcec7dcc5c.webp" alt="Vandas_Valuation_PS.png">Source: Fiscal.aiOn Stocktwits, retail traders are ‘bullish’ about&nbsp;Vanda as of early Monday.<figure class="image"><img style="aspect-ratio:725/444;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_7_43_31_AM_png_814cfe36d5.webp" alt="Screenshot 2025-12-29 at 7.43.31 AM.png" width="725" height="444"></figure>&nbsp;A retail watcher was already bracing for $10+ level early this week,&nbsp;<a href="https://stocktwits.com/ms0632/message/640275096">anticipating</a> “good news.” Another user said that, irrespective of the FDA decision, the company has other sales and opportunities to limit downside. Citing “big upside potential,” they&nbsp;<a href="https://stocktwits.com/djacks/message/640216881">said</a> they added more shares.In premarket trading on Monday, the stock climbed over 4% to $7.35.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-outperformed-vs-nvidia-microsoft-ai-stocks-2025/cL75psZREDr">Palantir Crushed Nvidia, Microsoft And Most AI Stocks In 2025 — And Investors Didn’t Care About Valuation</a>

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock

Vanda’s shares have surged since mid-November ahead of a pivotal FDA decision on tradipitant for motion sickness, a binary event that could unlock a new market and drive further upside, with additional regulatory catalysts ahead.

Equity

Vanda’s shares have surged since mid-November ahead of a pivotal FDA decision on tradipitant for motion sickness, a binary event that could unlock a new market and drive further upside, with additional regulatory catalysts ahead.


Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a more reasonable valuation.</li><li>Moderna continues to struggle post-pandemic, with weak fundamentals, no new blockbusters, and higher regulatory scrutiny weighing on its pipeline.</li><li>Analysts see greater upside for Super Micro than Moderna, while retail sentiment remains cautious toward both stocks.</li></ul>Investing in heavily shorted stocks isn't for the faint-hearted. While they can offer meaningful upside, that potential comes with heightened volatility and elevated risk. More often than not, they are shorted for legitimate reasons. But if the sentiment flips, these stocks can deliver explosive gains. The most-shorted S&amp;P 500 list currently includes two names that won't surprise many investors.&nbsp;Moderna — the biopharma that, along with Pfizer, led the COVID-19 vaccine race — rode a historic wave of demand during the pandemic. But as the outbreak faded and vaccine sales collapsed, the company's fundamentals have come under pressure despite efforts to sustain momentum with second-generation and combination shots. The company is still searching for its next blockbuster therapy.Super Micro Computer, Inc. (SMCI), which rode the artificial intelligence mania, selling AI servers, was once touted as a promising opportunity. The company, however, ran into rough weather in 2024 amid accusations of accounting issues, delays in filing of financial reports, and&nbsp;attacks from short-sellers.Since peaking at $122.90 on March 8, 2024, the stock has traded broadly downward for the rest of the year. Super Micro's addition to the S&amp;P 500 provided a boost, but it failed to reignite the uptrend. Notably, the company was removed from the Nasdaq 100 just five months after its inclusion in the tech index.<h2 class="st-heading-2">Stock Returns This Year</h2>As Super Micro became compliant with the listing requirements for timely quarterly reporting, buyers returned to the stock. The<a href="https://stocktwits.com/symbol/SMCI">&nbsp;SMCI stock</a> also benefited from the company's new offerings involving Nvidia's newest high-performance chips and its positive long-term outlook. Its near-term underperformance raised concerns among investors.&nbsp;After rising through the first quarter, Super Micro's stock pulled back and hit a low in mid-November and has been consolidating since.<a href="https://stocktwits.com/symbol/MRNA">Moderna's stock</a> was on a steady downward trajectory this year, barring occasional consolidation moves.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_stock_returns_png_dd55f22501.webp" alt="MRNA-SMCI stock returns.png">Source: Koyfin<h2 class="st-heading-2">Elevated Short Bets&nbsp;</h2>According to Koyfin, the short interest for Super Micro peaked in April (19.60%) before reducing to 14.70% currently. Moderna's short interest, though off its May peak of 17.40%, has declined by less than one percentage point.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_short_interest_png_9af30dca45.webp" alt="MRNA-SMCI-short interest.png">Source: Koyfin<h2 class="st-heading-2">Time To Revisit?</h2>Super Micro now trades at a relatively reasonable valuation (in terms of the forward price-earnings (P/E) multiple versus the tech sector and its peak multiple).<img src="https://news.stocktwits-cdn.com/SMCI_Forward_PE_png_d98fc94770.webp" alt="SMCI_Forward_PE.png">Source: Fiscal.aiModerna, on the other hand, trades at a much higher price-to-sales (P/S) multiple than it did last July. Since Moderna is projected to report losses over the next year, the P/E ratio isn't applicable.<img src="https://news.stocktwits-cdn.com/MRNA_Forward_PS_png_794682e423.webp" alt="MRNA_Forward_PS.png">Source: Fiscal.aiAccording to Koyfin-compiled consensus analysts' stock price targets for the companies,&nbsp; estimates, Super Micro has an upside potential of 39% versus 23% for Moderna.&nbsp;Super Micro has an equal share of analysts who are bullish and neutral on the stock. Meanwhile, more analysts are on the sidelines of Moderna (15 of the 22 analysts covering the stock).On Stocktwits, retail traders are 'bearish' on Super Micro as of early Thursday, while Moderna elicited 'neutral' sentiment.For Super Micro, simmering AI bubble fears could remain an overhang on the stock. Still, if the company can execute its plans and leverage its partnership with Nvidia, the stock could see a reversal in fortunes. Moderna, meanwhile, remains a "show-me" story as it has to prove the mettle of the rest of its pipeline. Moderna also faces regulatory uncertainty as the FDA applies heightened scrutiny to new vaccines and therapeutics, adding another layer of risk to its pipeline.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/powell-didn-t-surprise-how-retail-traders-are-positioning-after-fed-s-rate-cut/cLIx7TYREn2">&nbsp;Powell Didn't Surprise — But Markets Might: How Retail Traders Are Positioning After Fed's Rate Cut</a>

 Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2025 in New York City. After losing over 400 points on the first day of December, the market began to recover with the Dow up over 120 points in morning trading. 

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze?

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Health and Human Services Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee on Sept. 4 to discuss U.S. President Donald Trump’s healthcare agenda.Chairman Mike Crapo said the hearing will focus on “the Department of Health and Human Services’ Make America Healthy Again actions to date and plans moving forward,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-testify-before-senate-panel-health-agenda-2025-08-28/">reported</a>.The session comes after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdc-chief-susan-monarez-pushed-out-after-weeks-on-job-as-rfk-jr-overhauls-agency-she-s-fighting-back/chsCsP4Rdli">White House dismissed CDC Director Susan Monarez</a> on Wednesday, less than a month into her tenure. An associate said Monarez was fired after resisting vaccine policy changes advanced by Kennedy that she believed contradicted scientific evidence.&nbsp;Hours later, three senior officials — Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan — resigned and were&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/fired-cdc-director-clashed-with-kennedy-on-vaccine-policy-2025-08-28/">reportedly</a> escorted from the Atlanta campus.&nbsp;CDC staff, many wearing green shirts and ribbons as a sign of support, applauded them as they departed.Richard Besser, former acting CDC director, said Monarez told him she would not take any action that was illegal or “flew in the face of science,” and she refused to dismiss her leadership team without cause.&nbsp;The three departing officials said they resigned over anti-vaccine policies and misinformation promoted by Kennedy and his team. Daskalakis said, “I’m a doctor. I took the Hippocratic oath that said, ‘First, do no harm.’ I believe harm is going to happen, and so I can’t be a part of it.”Since taking office this year, Kennedy has fired the CDC’s vaccine advisory panel and replaced it with anti-vaccine activists and other advisers.&nbsp;He has made false claims about vaccines and launched an investigation into autism rates that he has linked, without evidence, to “environmental toxins.”&nbsp;The CDC has since dropped its recommendation that pregnant women be vaccinated against COVID and narrowed its guidance for children with health complications.White House spokeswoman Karoline Leavitt said Monarez was dismissed because she did not align with the president’s mission. “She said she would [resign], and then she said she wouldn’t, so the president fired her,” Leavitt said.&nbsp;Kennedy declined to comment on the specifics of the departures but told&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxnews.com/media/rfk-jr-warns-cdc-in-trouble-promises-fixes-director-refuses-step-down">Fox News</a>, “The agency is in trouble, and we need to fix it and we are fixing it. And it may be that some people should not be working there anymore.”&nbsp;Deputy HHS Secretary Jim O’Neill was named interim director of the CDC.Monarez’s dismissal is one of several recent moves by Trump to remove Senate-confirmed officials, including Federal Reserve Governor Lisa Cook and Surface Transportation Board member Robert Primus.On Stocktwits, retail sentiment was ‘bearish’ with ‘low’ message volume for both the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV).While&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has been flat so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has risen 4.6% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit

The White House's move to oust Susan Monarez and the wave of senior CDC resignations have spotlighted deep divisions over vaccine policy and raised fresh questions about the administration’s healthcare agenda.

U.S. Centers for Disease Control and Prevention Director Susan Monarez has left the agency less than a month after being sworn in, amid the resignation of four senior officials&nbsp;who also resigned over vaccine policy tensions.Monarez’s attorneys said she is challenging her ouster, accusing HHS Secretary Robert F. Kennedy Jr. of targeting her for rejecting “unscientific directives,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-chief-exits-after-weeks-role-three-top-officials-resign-2025-08-27/">reported</a>.&nbsp;“Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign,” lawyers Mark S. Zaid and Abbe David Lowell said.The U.S. Department of Health and Human Services' account on X shared a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/HHSGov/status/1960818490614415869">post</a> about Monarez's exit, saying: "We thank her for her dedicated service to the American people. @SecKennedy has full confidence in his team at @CDCgov who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad."CDC Chief Medical Officer Debra Houry and Immunization Center Director Demetre Daskalakis have resigned, citing the rise in health misinformation, attacks on science, and budget cuts.&nbsp;Infectious Diseases Director Daniel Jernigan and Public Health Data Director Jen Layden also stepped down. Houry wrote that overstated risks and misinformation have fueled record measles cases and even a violent attack on the CDC.The White House’s 2026 budget proposed cutting CDC funding by $3.6 billion, while Kennedy had already eliminated 2,400 jobs and rehired 700. Daskalakis said he could not serve amid the “ongoing weaponizing of public health.”The CDC has faced mounting strain under Kennedy, including a shooting at its Atlanta headquarters. Former CDC official Fiona Havers called the latest resignations “devastating,” saying the departed leaders had shielded scientists from political attacks.Kennedy has rolled back vaccine policies, withdrawing COVID shot recommendations for children and pregnant women, and firing all members of the CDC vaccine advisory panel in June, replacing them with hand-picked advisers, including vaccine skeptics.&nbsp;On Wednesday, he announced further changes to COVID-19 vaccine eligibility and stated that autism policy announcements are expected in September.Monarez, a federal scientist, was confirmed on July 29 after being nominated by U.S. President Trump and sworn in by Kennedy on July 31. She succeeded Trump’s withdrawn pick, former congressman and vaccine critic Dave Weldon.&nbsp;On Stocktwits, retail sentiment was bearish for both the iShares Biotechnology ETF (IBB) with normal message volume, and the Health Care Select Sector SPDR Fund (XLV) with low message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has gained 4.9%, while&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has increased by 0.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monarez is a health scientist with a Ph.D. in microbiology and immunology who previously served as the Deputy Director of the Advanced Research Projects Agency for Health. (Photo by Kayla Bartkowski/Getty Images)

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back

The sudden leadership shake-up at the CDC deepens turmoil inside the agency, where multiple senior officials have also resigned over vaccine policy disputes with Health Secretary Robert F. Kennedy Jr.

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBB News

IBBiShares Biotechnology ETF